EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Valbiotis SAS (ALVAL) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Valbiotis SAS €0.11, price €0.70, upside -84.2%, quality 31 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Consumer Defensive · FR · ISIN FR0013254851

VS Thin data Sep 23, 2026

Valbiotis SAS

ALVAL · PA

Weakest SetupStrongly overvalued and low quality.

!Fair value €0.1105 · Strongly overvalued (−84%)
!Quality 31/100
!Weak Growth (revenue 5y −21.8 %/yr)
!Low debt · negative free cash flow
!Trails peers (1/8)
!Narrow moat 6/100
!Evidence only low, so the estimate is less certain
Watch Valbiotis SAS for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€7.18 €0.5409 Fair Value €0.1105 Aug 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range €0.5409 – €7.18 · fair‑value band €0.0680 – €0.1360 · the €0.7010 price screens above the €0.1105 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow Valbiotis SAS in your weekly email

Every Wednesday you see whether Valbiotis SAS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort.

Show more

Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. It also develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis. Additionally, the company offers e-commerce delivery service in Belgium and Luxembourg. Valbiotis SA was incorporated in 2014 and is based in Périgny, France.

Stock analysis

Valbiotis SAS (ALVAL) currently trades at €0.7010, while our model-based Fair Value estimate is €0.1105, implying the stock looks roughly 534.5% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: €0.0680 (bear) to €0.1360 (bull), the price of €0.7010 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 31/100 (below-average quality), in the Consumer Defensive sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Valbiotis SAS reported revenue of €905K in FY2025 versus €298K in FY2021, a compound +32.0%/yr. Reported net income was −€9.4M in FY2025.

Key figures

Market cap €28.2M · P/S ratio 31.1 · EPS (TTM) €−0.4600 · Return on equity −109% · Return on assets (EBIT) −46.1% · Operating margin −844% · Revenue (TTM) €905K · Revenue growth (YoY) +306%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).

What moves the price

The share trades about 41% below its 52-week high and 30% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Consumer Defensive peers we cover trades at −2% fair-value upside, at −84%, ALVAL screens richer than that median.

Fair Value models

Bear €0.0680 Fair Value €0.1105 Bull €0.1360
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) €0.1000 €0.1300 €0.2000 53
All 1 models by family
Asset-Based
NCAV (Graham) €0.1000 €0.1300 €0.2000 53

Open the full fair value analysis →

Notify me when ALVAL reaches fair value

Put ALVAL on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 31/100

Of which business quality 32 · Market factors (momentum, volatility) 32

Profitability 0
Margins and returns on capital today
Quality Growth 75
Are margins and returns improving?
Cashflow 8
Earnings quality: real cash, not paper profit
Fin. Strength 60
Balance sheet, leverage, solvency risk
Investment 73
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 25
Price trend over the last 3–12 months (market factor)
52W Momentum 24
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−21.8%
Start year 2020 (pandemic). Over 10 years: +56.9% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+56.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−175.1% (2020) → −1,049.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ALVAL screens 535% overvalued. Compare with Nestlé S.A →

Compare Valbiotis SAS with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 668 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Bottom 25%
Fair Value upside −85% · Bottom 25%
Profitability
Return on assets −35% · Bottom 25%
Growth and dividend
Revenue growth 306% · Top 25%
Balance sheet
Debt / equity 0.32× · Above median

Valuation Multiplesvs Packaged Foods median · lower = cheaper

P/B 4.61× · Priciest 25%
P/S (TTM) 35.44× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 30
FUTURE (revenue growth)100 · sector 20
PAST (return on equity)0 · sector 29
HEALTH (low debt)84 · sector 96
DIVIDEND (yield)0 · sector 58

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Packaged Foods stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Nestlé S.A NESN CHF 77.09 CHF 59.49 −23%
Danone S.A BN €60.90 €50.81 −17%
The Kraft Heinz Company KHC $24.00 $29.20 +22%
Foshan Haitian Flavouring and Food Company 603288 ¥34.29 ¥37.72 +10%
Nestlé India Limited NESTLEIND ₹1,387 ₹724.74 −48%
Inner Mongolia Yili Industrial Group 600887 ¥26.77 ¥41.84 +56%
Yihai Kerry Arawana Holdings 300999 ¥25.12 ¥9.98 −60%
General Mills, Inc GIS $35.45 $34.66 −2%
Uni-President Enterprises Corp 1216 74.50 TWD 68.72 TWD −8%
McCormick & Company MKC $49.42 $51.01 +3%

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Valbiotis SAS · Fair Value
€0.1105 −535%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Valbiotis SAS Fair Value". https://www.fairvalue-calculator.com/stock/ALVAL

Frequently asked questions

Is Valbiotis SAS (ALVAL) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of €0.1105 versus a price of €0.7010, about −84% upside (overvalued).
What is the fair value of ALVAL?
Our model-based fair value for Valbiotis SAS is €0.1105 (as of Sep 23, 2026), built from audited fundamentals. The current price: €0.7010.
What is the quality score of ALVAL?
Valbiotis SAS has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Valbiotis SAS (ALVAL)?
Our model-based price target is the fair value of €0.1105 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario €0.0680, optimistic scenario €0.1360. It is a calculation from audited fundamentals, not an analyst target.
What is the Valbiotis SAS stock forecast for 2026?
Our models put fair value at €0.1105, about −84% upside versus a price of €0.7010 (overvalued). Cautious scenario €0.0680, optimistic scenario €0.1360. The calculation is refreshed regularly with new filings.
What is the revenue of Valbiotis SAS (ALVAL)?
Valbiotis SAS reported trailing-twelve-month revenue of about €905K (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Valbiotis SAS (ALVAL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Valbiotis SAS it is €0.1105 per share (as of Sep 23, 2026), against a price of €0.7010. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Valbiotis SAS stock overvalued or undervalued in 2026?
As of Sep 23, 2026, ALVAL trades above its calculated fair value: price €0.7010, fair value €0.1105, a gap of about −84% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALVAL?
No. The price is what the market pays today (€0.7010); the fair value is what the company's own numbers justify (€0.1105). For Valbiotis SAS the two are €0.5905 per share apart. That gap is exactly why we show both numbers side by side.
How much is Valbiotis SAS worth?
The market values Valbiotis SAS at about €28.2M (market capitalisation, as of Sep 23, 2026). Per share that is €0.7010; our models calculate a fair value of €0.1105 per share.
What do the bullish and bearish scenarios say about ALVAL?
Our models span a range for Valbiotis SAS: cautious scenario €0.0680, base €0.1105, optimistic €0.1360 per share (as of Sep 23, 2026, price €0.7010). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Valbiotis SAS (ALVAL)?
Balance-sheet figures for Valbiotis SAS (as of Sep 23, 2026): return on equity −108.7%, debt of 0.32 per unit of equity. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is ALVAL from its 52-week high?
Valbiotis SAS trades at €0.7010, about 41% below its 52-week high of €1.19 and 30% above the low of €0.5409 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of €0.1105 is for.
Which stocks are comparable to Valbiotis SAS?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, The Kraft Heinz Company, Foshan Haitian Flavouring and Food Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Valbiotis SAS stock attractive at the current price?
The data as of Sep 23, 2026: price €0.7010, calculated fair value €0.1105 (−84%), Quality Score 31/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ALVAL calculated?
We run Valbiotis SAS through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €0.1105, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Valbiotis SAS itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Valbiotis SAS (ALVAL)?
The closing price on Sep 24, 2026 was €0.7010. Our model-based fair value is €0.1105, about −84% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Valbiotis SAS right now?
The price sits above even our optimistic bull case (€0.1360). The favourable scenario is already priced in. Weak quality (31/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (€0.0680 to €0.1360) leaves room in how you read the outcome.

Key figures of Valbiotis SAS

How large is the market capitalisation of Valbiotis SAS (ALVAL)?
The market capitalisation of Valbiotis SAS is €28.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Valbiotis SAS (ALVAL)?
The price-to-sales ratio of Valbiotis SAS is 31.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Valbiotis SAS (ALVAL)?
Earnings per share at Valbiotis SAS are €−0.4600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Valbiotis SAS (ALVAL)?
The return on equity (ROE) of Valbiotis SAS is −109% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Valbiotis SAS (ALVAL)?
On an EBIT basis the return on assets of Valbiotis SAS is −46.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Valbiotis SAS (ALVAL)?
The operating margin of Valbiotis SAS is −844% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Valbiotis SAS (ALVAL)?
Revenue at Valbiotis SAS is growing +306% versus a year earlier (3y avg +4.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Valbiotis SAS (ALVAL) generate?
The free cash flow of Valbiotis SAS is −€8.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Valbiotis SAS (ALVAL) hold?
Valbiotis SAS holds more cash than debt, €3.6M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Valbiotis SAS in the live analysis

One click puts Valbiotis SAS on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.